IFNAR1
Interferon alpha/beta receptor 1
As of the edition of 20 October 2026, IFNAR1 (interferon alpha/beta receptor 1, UniProt P17181) has 14 drugs tested at it and 9 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P17181
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 5
- Disease areas
- Infections; Digestive system; Immune system; Cancer; Nervous system; Urinary and reproductive; Skin and connective tissue; Blood and lymph
- Registered trials of its drugs
- 1,019
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 12 |
| Active | 2 |
| Total | 14 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Peginterferon alfa-2a | Marketed | Phase 4 | Ended 2014 |
| Peginterferon alfa-2b | Marketed | Phase 4 | Ended 2013 |
| Interferon alfa-2b | Marketed | Phase 4 | Ended 1998 |
| Interferon beta-1a | Marketed | Phase 4 | Ended 2008 |
| Interferon beta-1b | Marketed | Phase 4 | Ended 2005 |
| Interferon | Marketed | Phase 4 | none listed |
| Anifrolumab | Marketed | Phase 4 | Ends 2033 |
| Ropeginterferon alfa-2b | Marketed | Phase 4 | Ends 2033 |
| Interferon alfa-2a | Marketed | Phase 3 | Ended 1998 |
| Peginterferon beta-1a | Marketed | Phase 4 | Ended 2026 |
| Interferon beta | Active | Phase 3 | none listed |
| Albinterferon alfa-2b | Active | Phase 2 | none listed |
12 of 14 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 8 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
The other 8 companies at IFNAR1
In the product9 companies in all; 8 are not named here, and no score is.
See the 9 companies at IFNAR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.